Premium
RNA TREATMENT OF DEMENTIA
Author(s) -
MunchPetersen S.,
Pakkenberg H.,
Kornerup H.,
Ortmann J.,
Ipsen E.,
Jacobsen P.,
Simmelsgård H.
Publication year - 1974
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1974.tb02801.x
Subject(s) - pneumoencephalography , atrophy , dementia , uric acid , placebo , depression (economics) , medicine , creatinine , clinical trial , gastroenterology , endocrinology , pathology , disease , radiology , alternative medicine , macroeconomics , economics
Uridine uptake in the nerve cells of the cortex in mice was demonstrated by autoradiography after oral administration of H 3M ‐uridine. Following this trial a clinical treatment was carried out. The material consisted of twenty‐two mental hospital patients with mild to moderate degrees of dementia. Ten of these patients received treatment by oral administration of about 20 g hydrolyzed yeast‐RNA daily over a period of 4 months, while 12 patients received placebo. A psychological investigation and a clinical evaluation were performed prior to, during and immediately after the investigation, as well as 2 months later. Furthermore, a neurological investigation, EEG, determination of serum uric acid, serum creatinine and serum cholesterol were all made simultaneously with the psychological tests. Pneumoencephalography was performed in 12 patients prior to the start of the investigation (7 of these showed moderate, diffuse atrophy, and 5 showed severe, diffuse atrophy). In general, it may be concluded that there was no change in the state of dementia as a result of the treatment given.